NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/02/2025
Back to search
Official data from USPTO
RAKUTEN MEDICAL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
RAKUTEN MEDICAL
ST13
US500000090981512Class
35, 41, 42, 44
Filing
90981512
Registration
8052456
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
66
Latest update
12/03/2025
Trademark type
Word
Nice classes
35, 41, 42, 44
Filing date
11/11/2020
Registration date
12/02/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/02/2025
Last transaction
12/03/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
01/10/2023
First use in commerce
01/10/2023
Drawing code
4
Owner type
03
Owner location
SETAGAYA-KU, TOKYO, JP
Examiner
IN,SUNG HYUN
Law office
L30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
RAKUTEN GROUP, INC.
Rakuten, Inc.
Representatives
Anna Kurian Shaw HOGAN LOVELLS US LLP
Technical classification
Nice Classes
Class 35Class 41Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 35
Compilation of statistical data relating to medical research for business purposes
Class 41
Educational servicesproviding training in the field of medicinesmedical devicespharmaceuticalsclinical trials and health care; Teaching and training servicescoursesclasseslessons and seminars in the field of medicinespharmaceuticals and health care; Arrangingconducting and organization of congressesconferencesconventions and symposiums in the field of medicinespharmaceuticals and health care; Educational servicesproviding classesseminarslecturesall in the field of the diagnosis and treatment of cancer; education in the nature of classesseminarstraining in the oncology field
Class 42
Testing and research on medical treatment methods and techniques; Provision of medical and scientific research information on clinical trials; Research and development in the field of immunology; Testing and research on pharmaceuticals; Medical and pharmacological research services and clinical trials for others; Researchdevelopmentconsultation related thereto in the field of medicine; Providing medical and scientific research information in the field of pharmaceuticals; Pharmaceutical drug development services; Medical laboratories; Design and development of medical technology; Scientificbiological and medical research; Conducting clinical trials for others
Class 44
Medical services; Medical information; Providing medical information from a web site; Medical testing for diagnostic or treatment purposes; Medical treatment services; Medical care services; Medical analysis services relating to the treatment of persons provided by a medical laboratory; Medical services in the field of oncology; Medical consultation; Medical advisory services; Compilation of medical reportsmedical reporting services; Issuing of medical reportsmedical reporting services; Medical and healthcare clinics; Medical assistance; Healthcare services; Rental of medical machines and apparatus; Consultancy and information services relating to the diagnosticprophylactictherapeutic properties of medical products; Providing information in the field of health caremedical conditionsmedicine and pharmaceuticals; Providing medical information on pharmaceuticals and oncology platforms; Providing medical and patient support information in relation to the treatment of cancer; Counselling servicesmedical counselling for patients diagnosed with cancer; Information services in the field of diagnosing and treating cancer; Providing online information servicesprescription drug information regarding diagnosticprophylactictherapeutic properties; Providing information in the field of medicine; Providing medical information regarding medical conditions and diseases and providing information relating to the health effects of pharmaceuticals; Providing information and content about cancercancer recoverycancer treatmentpost-cancer treatment care and survival via a website; Providing information about cancercancer recoverycancer treatmentpost-cancer treatment care and survival via an online searchable database; Medical diagnostic testing and reporting services; Genetic testing for diagnostic and treatment purposes; Providing healthcare information regarding cancer drugs and cancer treatment; Maintaining personal medical history records and files
Publications
History of USPTO decisions and trademark events.
66 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/02/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
11/12/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/12/2025
DPCC
DIVISIONAL PROCESSING COMPLETE
10/27/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/23/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
08/28/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/28/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
08/28/2025
SNEA
SU-EXAMINER'S AMENDMENT WRITTEN
08/28/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/14/2025
GNRT
NON-FINAL ACTION E-MAILED
05/14/2025
CNRT
SU - NON-FINAL ACTION - WRITTEN
05/14/2025
ALIE
ASSIGNED TO LIE
12/14/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/13/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/13/2024
DRRR
DIVISIONAL REQUEST RECEIVED
11/14/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/14/2024
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
11/14/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/09/2024
GNRT
NON-FINAL ACTION E-MAILED
09/09/2024
CNRT
SU - NON-FINAL ACTION - WRITTEN
09/09/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
08/07/2024
IUAF
USE AMENDMENT FILED
08/05/2024
EISU
TEAS STATEMENT OF USE RECEIVED
08/05/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/22/2024
EX5G
SOU EXTENSION 5 GRANTED
02/21/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
02/21/2024
EXT5
SOU EXTENSION 5 FILED
02/05/2024
EEXT
SOU TEAS EXTENSION RECEIVED
02/05/2024
DOCK
ASSIGNED TO EXAMINER
10/26/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/10/2023
EX4G
SOU EXTENSION 4 GRANTED
08/08/2023
EXT4
SOU EXTENSION 4 FILED
08/08/2023
EEXT
SOU TEAS EXTENSION RECEIVED
08/08/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/25/2023
EX3G
SOU EXTENSION 3 GRANTED
01/23/2023
EXT3
SOU EXTENSION 3 FILED
01/23/2023
EEXT
SOU TEAS EXTENSION RECEIVED
01/23/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/09/2022
EX2G
SOU EXTENSION 2 GRANTED
08/05/2022
EXT2
SOU EXTENSION 2 FILED
08/05/2022
EEXT
SOU TEAS EXTENSION RECEIVED
08/05/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/22/2022
EX1G
SOU EXTENSION 1 GRANTED
01/20/2022
EXT1
SOU EXTENSION 1 FILED
01/20/2022
EEXT
SOU TEAS EXTENSION RECEIVED
01/20/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
08/10/2021
CHPB
POST PUBLICATION AMENDMENT - ENTERED
07/20/2021
APET
ASSIGNED TO PETITION STAFF
07/19/2021
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
06/24/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/15/2021
PUBO
PUBLISHED FOR OPPOSITION
06/15/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/26/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/10/2021
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
05/05/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
04/23/2021
GNSL
LETTER OF SUSPENSION E-MAILED
04/23/2021
CNSL
SUSPENSION LETTER WRITTEN
04/23/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
04/23/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/23/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
04/23/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/23/2021
DOCK
ASSIGNED TO EXAMINER
04/14/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/11/2021
NWAP
NEW APPLICATION ENTERED
11/14/2020
Continuous trademark protection
Get notified about every new filing that threatens RAKUTEN MEDICAL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.